VXRT Stock Overview
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.
Vaxart, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.08|
|52 Week High||US$7.61|
|52 Week Low||US$1.07|
|1 Month Change||-26.53%|
|3 Month Change||-61.84%|
|1 Year Change||-82.99%|
|3 Year Change||234.83%|
|5 Year Change||n/a|
|Change since IPO||-87.29%|
Recent News & Updates
Companies Like Vaxart (NASDAQ:VXRT) Are In A Position To Invest In GrowthAug 25
We're Hopeful That Vaxart (NASDAQ:VXRT) Will Use Its Cash WiselyMay 11
Shareholders Are Thrilled That The Vaxart (NASDAQ:VXRT) Share Price Increased 231%Mar 03
We're Interested To See How Vaxart (NASDAQ:VXRT) Uses Its Cash Hoard To GrowFeb 10
How Much Of Vaxart, Inc. (NASDAQ:VXRT) Do Institutions Own?Jan 20
Market Sentiment Around Loss-Making Vaxart, Inc. (NASDAQ:VXRT)Dec 22
Wouter Latour Is The Chairman of Vaxart, Inc. (NASDAQ:VXRT) And They Just Sold 100% Of Their SharesNov 26
What Does The Future Hold For Vaxart, Inc. (NASDAQ:VXRT)? These Analysts Have Been Cutting Their EstimatesNov 19
|VXRT||US Biotechs||US Market|
Return vs Industry: VXRT underperformed the US Biotechs industry which returned -11.2% over the past year.
Return vs Market: VXRT underperformed the US Market which returned -20.6% over the past year.
|VXRT Average Weekly Movement||12.2%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: VXRT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: VXRT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.
Vaxart, Inc. Fundamentals Summary
|VXRT fundamental statistics|
Is VXRT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VXRT income statement (TTM)|
|Cost of Revenue||US$76.13m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.80|
|Net Profit Margin||-65,788.68%|
How did VXRT perform over the long term?See historical performance and comparison